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High-dose inactivated, influenza vaccine was licensed by the FDA in December 2009 for adults aged 65 y and older.
The ACIP did not issue or state a preference for a specific vaccine in the elderly population. The extent of its on-label
and off-label use is unknown. Using the MarketScan Commercial Claims and Encounters and the Medicare
Supplemental database, we identified individuals who received the high-dose influenza vaccine or the standard,
seasonal trivalent influenza vaccine between January 1, 2010 and December 31, 2012. For people aged 65 y, we used
multivariable regression to assess the association between patient and provider level variables and high-dose influenza
vaccine versus standard influenza vaccine. We characterized all off-label high-dose vaccine administered to people
younger than 65 y of age, and investigated whether sicker patients were targeted for off-label use by examining the
association between various comorbid conditions and receipt of the high-dose vaccine among adults aged 18–64.
Among patients aged 65 y who received an influenza vaccine, 18.4% received the high-dose vaccine. Uptake was
minimal in 2010, but 25% and 32% of influenza shots were the high-dose formulation in 2011 and 2012, respectively.
Almost 27,000 seniors received a second high-dose vaccine with a median of 368 d (IQR: 350–387 days) between doses.
Older age, family practice physicians, and having PPO insurance were positively associated with receiving high-dose
vaccine. There were 36,624 off-label high-dose vaccines administered. Half of the patients receiving off-label doses
were aged 50–64. Adults aged 18–64 y receiving high-dose vaccine were more likely to have chronic comorbidities
than people receiving standard influenza vaccine; however, there was not one specific illness that seemed to be
targeted by physicians. In the first 3 y since licensure, use of the high-dose vaccine among seniors has been limited. The
safety of this vaccine should be monitored closely among 2 groups of people - seniors receiving repeat doses and
people <65.
Introduction
Each year, it is estimated that on average 36,000 people die
from influenza in the United States, with a majority occurring in
the elderly population.1 It is becoming increasingly clear that
elderly people have a decreased immune response to standard
influenza vaccines as compared to healthy adults, most likely due
to immune senescence.2,3 In December 2009, a new high-dose
influenza vaccine was licensed for elderly people aged 65 y and
older.4 This vaccine contains the same 3 strains as standard sea-
sonal influenza vaccines, but has 4 times as much antigen (60 mg
per strain compared to 15 mg per strain for the standard vaccine).
Although small efficacy studies have been conducted and show
increased immune response after administration of the high-dose
vaccine,5–9 no population-based effectiveness studies have been
performed. Results from a post-licensure randomized controlled
efficacy trial including »32,000 patients suggested that the high-
dose vaccine was 24.2 % (95% CI: 9.7%, 36.5%) more effective
in preventing influenza than the standard vaccine.10 However,
these results have not been formally published, and the recom-
mendation for the 2013–2014 influenza season by the Advisory
Committee on Immunization Practices (ACIP) remained the
same as previous years – that there was no preference between the
high-dose and standard, seasonal vaccines for the elderly aged
65 y.11 Therefore, the decision is left to the physician/provider
as to which vaccine to administer. As the market for different
types and formulations of influenza vaccines is increasing each
year, it is important to understand administration patterns for
both on-label use among people aged 65 y and off-label use
among people aged <65 y. Understanding the uptake of this vac-
cine will also encourage further monitoring of safety and effec-
tiveness in the populations that are using it.
We use the first 3 y of post-licensure data from a large seg-
ment of commercially insured adults and from elderly patients
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with employee sponsored Medicare supplemental insurance to
study the uptake of high-dose influenza vaccine. We investigate
individual and provider level predictors of on-label use and char-
acterize comorbidity patterns among patients who receive off-
label vaccine.
Results
Among the 1,208,173 patients 65 y who received an influ-
enza vaccine between 2010 and 2012, 221,853 (18.4%) received
the high-dose vaccine. Uptake was minimal in 2010 (5.6% of all
influenza shots administered between August and December),
but 25% and 32% of influenza shots were the high-dose formula-
tion in 2011 and 2012, respectively (Fig. 1). Fifteen percent of
seniors meeting inclusion criteria and who received an initial
high-dose vaccine had a second high dose vaccine (N D 26,857)
with a median of 368 d (IQR: 350–387 days) between doses,
indicating that most of these repeat vaccinees received one high
dose vaccine per influenza season. Patients 75 y or older were
more likely to receive the high-dose vaccine, while males, patients
with HIV and patients with liver disease were less likely to receive
the vaccine. There was some indication that the high-dose vac-
cine was being used more frequently in patients with past comor-
bidities (i.e. transplant patients, stroke, pneumonia); however,
these effects were very small (Table 1). All other comorbidities
were not strongly associated with high-dose vaccine. These rela-
tionships were similar when using a 6-month window and an 8-
month window to assess comorbidities (Appendix 2). Provider
level characteristics that were associated with high-dose vaccine
included provider type and insurance type (Table 1). Family
practice physicians, pharmacists and nurses were more likely to
administer the vaccine compared to internal medicine physicians,
and patients with health maintenance organization (HMO)
insurance were less likely to receive high-dose vaccine compared
with preferred provider organization (PPO) insurance. Finally,
there may be some indication of regional variation, with the
North Central and the South regions being more likely to admin-
ister the high-dose vaccine.
There were 36,624 doses of off-label high-dose vaccine
administered to patients less than 65 y of age. Off-label adminis-
tration increased 49% from 2010 to 2011, but was slightly less in
2012 (Fig. 2). Among patients with 4 months of enrollment
prior to vaccination (N D 34,497), the majority of off-label doses
were given to adults aged 51–64 (Table 2). However; 7.3% of
off-label doses were given to children. There were no clear
comorbidity patterns among off-label vaccinees – only 26% had
some immune-compromising or chronic condition. Other
comorbidities that were the most common among off-label recip-
ients were hypertension and diabetes (Table 2). When compared
to adults aged 18–64 who received the standard seasonal vaccine,
high-dose recipients were more likely to have an immune-
compromising condition (23% more likely), heart disease
(30%), chronic lung disease (25%), diabetes (28%) and hyper-
tension (17%) (Table 3). Family practice physicians, pharmacists
and nurses were much less likely to administer the high-dose vac-
cine compared to internal medicine physicians (Table 3).
Discussion
In the first 3 influenza seasons since licensure, the uptake of
high-dose influenza vaccine among the elderly has been limited.
Among this population of patients with Medicare Supplemental
insurance, we show that only 18.4% of influenza shots were
high-dose vaccine. Interestingly, almost 27,000 people received
multiple high-dose vaccines. While small studies have reported a
potential for an increased rate of minor adverse events after one
shot (i.e., redness and pain at the injection site, gastrointestinal
upset),12–14 there has been no safety assessment for multiple
doses.
There may be several reasons why uptake of this vaccine has
been slow. Physicians may be hesitant to suggest this new vaccine
to their patients, especially since the ACIP has not issued a prefer-
ence for the high dose vaccine. Additionally, access to the vaccine
may be another barrier. Stocking another type of influenza vac-
cine may increase cost and logistics for physician offices, particu-
larly for physicians who don’t have a history of stocking adult
vaccines. Our study suggested that family practice physicians
were more likely to administer the high dose vaccine than inter-
nal medicine physicians, which may be explained by a higher
proportion of family physicians stocking all adult vaccines.15
Cost and inadequate reimbursement have also been documented
as significant barriers for physicians in administering other adult
vaccines.16,17 In an environment with increasing options of influ-
enza vaccine type (administration route, dose, strain) further
research is needed to determine the rationale for which vaccine is
administered by providers.
Older age was one of the stronger predictors of on-label high
dose vaccine use. Providers may be administering the high dose
vaccine to older patients in response to immune senescence.
Physicians may also be more willing to try a new vaccine in
patients where the risk of severe disease far outweighs the poten-
tial for minor adverse effects, which could be the scenario in the
very old.
Figure 1. Doses of influenza vaccine administered to people aged 65 y
by month and vaccine type, 2010–2012.
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There was a surprising amount of off-label use of the high
dose vaccine. While off-label use of medications is common par-
ticularly for oncology treatment,18 antipsychotic medications19
and the use of biologics to treat rheumatoid arthritis,20 use of
vaccines off-label is rare. We found only one recent study that
reported the use of Tdap among elderly people.21 It is possible
that some of the off-label use we report is due to coding errors,
particularly in children. The code for the high-dose vaccine is
only 1 digit different from the live virus vaccine, commonly given
to children. However, it is less likely coding errors can explain the
adult usage, as the codes for all other adult influenza vaccine for-
mulations have 2 digits that are different from the high-dose
code.
We did not see a clear pattern of specific comorbidities among
adults aged 18–64 y given high-dose vaccine. Only 26% of all
off-label users had a recent diagnosis of an immune-related
Table 1. Predictors of high-dose influenza vaccine use for eligible seniors 65 y and over, 2010–2012
High dose vaccine, N % Crude OR (95% CI) Multivariable adjusted* OR (95% CI)
Total vaccinated 212,030 18.6 — —
Age
65–74 108,285 51.0 Reference Reference
75C 103,745 48.9 1.19 (1.18, 1.21) 1.27 (1.26, 1.29)
Male sex 93,851 44.3 0.94 (0.93, 0.95) 0.94 (0.93, 0.95)
Comorbidities
Hypertension 130,062 61.3 1.04 (1.03, 1.05) 1.09 (1.08, 1.10)
Infection 81,375 38.4 1.04 (1.03, 1.05) 1.08 (1.07, 1.10)
IHD 77,029 36.3 1.03 (1.02, 1.04) 1.07 (1.06, 1.09)
Diabetes 59,109 27.9 1.01 (1.00, 1.02) 1.01 (1.00, 1.02)
COPD 30,796 14.5 0.98 (0.97, 0.99) 1.02 (1.00, 1.03)
Cancer 28,515 13.5 0.97 (0.96, 0.99) 1.05 (1.03, 1.07)
Autoimmune 12,194 5.8 1.01 (0.99, 1.03) 1.06 (1.04, 1.08)
Stroke 11,428 5.4 1.06 (1.04, 1.08) 1.09 (1.06, 1.11)
Pneumonia 5,665 2.7 1.05 (1.02, 1.08) 1.02 (0.99, 1.06)
Transplant 3,104 1.5 1.09 (1.05, 1.14) 1.08 (1.03, 1.13)
Liver disease 2,169 1.0 0.85 (0.81, 0.89) 0.94 (0.89, 0.99)
MI 1,839 0.9 1.00 (0.95, 1.05) 0.97 (0.91, 1.02)
Sepsis 1,451 0.7 0.90 (0.86, 0.96) 0.87 (0.83, 0.95)
HIV 80 0.04 0.36 (0.29, 0.45) 0.49 (0.38, 0.63)
Hospitalization 18,895 8.9 1.05 (1.04, 1.07) 1.02 (1.00, 1.04)
Pneumococcal vaccine 18,395 8.7 1.11 (1.09, 1.12) 1.08 (1.06, 1.10)
Provider type
Internal medicine 58,260 30.3 Reference Reference
Family practice 93,386 48.5 1.81 (1.79, 1.83) 1.64 (1.62, 1.66)
Specialist 14,241 7.4 0.78 (0.76, 0.79) 0.81 (0.80, 0.83)
Pharmacist 3,321 1.7 1.65 (1.58, 1.72) 1.72 (1.65, 1.79)
Nurse 2,123 1.1 1.52 (1.45, 1.59) 1.19 (1.13, 1.25)
Hospital 8,059 4.2 1.00 (0.98, 1.03) 0.84 (0.81, 0.86)
Other 13,223 6.9 0.74 (0.72, 0.75) 0.69 (0.68, 0.71)
Medicare Plan type
PPO 97,506 47.3 Reference Reference
Comprehensive 65,858 32.0 1.38 (1.36, 1.40) 1.59 (1.57, 1.61)
HMO 33,747 16.4 0.52 (0.52, 0.53) 0.62 (0.61, 0.63)
Other 8,938 4.3 0.80 (0.78, 0.81) 1.04 (1.01, 1.07)
Region
Northeast 39,902 18.8 Reference Reference
North central 75,171 35.5 2.29 (2.26, 2.32) 1.87 (1.84, 1.90)
South 59,853 28.2 1.91 (1.88, 1.94) 1.84 (1.81, 1.87)
West 33,867 16.0 1.03 (1.01, 1.05) 1.09 (1.08, 1.11)
Unknown 3,237 1.5 1.78 (1.71, 1.85) 1.40 (1.35, 1.47)
Rurality
Metropolitan 22,905 10.8 Reference —
Urban, nonmetro 2,899 1.4 0.90 (0.86, 0.93) —
Rural 340 0.2 1.09 (0.98, 1.22) —
Missing 185,886 87.7
IHDD Ischemic heart disease; COPD D Chronic obstructive pulmonary disease; MI DMyocardial infarction; HIV D Human immunodeficiency virus.
*Adjusted for month of vaccine receipt and all other variables in the table except for rurality
**Rurality was assessed in 2010 only. All other variables were measured in all years.
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condition (27% of off-label adults less than 50 y). However;
when compared to adults aged 18–64 who received the standard
influenza vaccine, high-dose recipients did appear to be sicker.
Adult patients receiving high-dose vaccine were more likely to
have an immune-compromising condition, heart disease, chronic
lung disease, diabetes and hypertension. However; the majority
of the population receiving off-label high-dose vaccine did not
have a severe, immune-related condition. Therefore, additional
studies should investigate further why health care personnel are
administering high dose vaccine to people younger than 65 y.
There were several limitations to this study. First, we may
have underestimated the use of all types of influenza vaccine in
both the elderly and the general population if people paid for the
vaccine in other ways than through their insurance (i.e., paid
out-of-pocket or received the vaccine through their employer).
For the analysis done in the elderly population, if people were
more likely to pay out-of-pocket for the standard vaccine because
it is cheaper, then the absolute estimates would be biased upward
and actual use of the high-dose vaccine could be lower. However,
Medicare covers both vaccines under Part B and therefore, miss-
ing vaccine may be less likely in the elderly population. For the
younger population, we felt that it was likely that claims for the
standard, seasonal vaccine could be missing if people received the
vaccine through an employer or paid out-of-pocket. One study
suggested that workplaces were the third most common place
that adults received the influenza vaccine,22 therefore it is likely
that some claims for standard vaccine were missing. If this miss-
ingness was different for those who had chronic disease vs. those
who did not, then we may have overestimated the association
between the comorbidity and high-dose vaccine use. Addition-
ally, it is possible that we missed off-label use of the high-dose
vaccine. It is unclear whether insurance companies would pay for
these shots for people younger than 65, and therefore, it is possi-
ble that physicians did not submit claims for off-label use. There-
fore, we suggest interpreting the comparison between high-dose
and seasonal vaccine in the younger population with caution.
Second, we used a 4 month window to search for comorbidities
that could be associated with both on and off-label use. This
would only identify people with recent claims for these condi-
tions and could miss people with well managed chronic illness.
When we increased the window to 6 and 8 months prior to
administration of the vaccine, we did identify more comorbid-
ities; however the association with receiving high-dose vaccine
remained similar. Third, we used ICD-9-CM codes to identify
comorbidities. This method can be less sensitive in identifying
conditions, and certain conditions contain many codes making
them less specific. We did provide all codes that were used to
allow others to replicate these comorbidity groupings. Finally, we
assessed use of on-label vaccine among a population of seniors
with Medicare supplemental insurance. This population could
be different than the general Medicare population, which could
limit generalizability. However, in 2012, 1 in 3 Medicare benefi-
ciaries had supplemental insurance through an employer23 –
therefore our study would directly apply to a large portion of the
elderly population.
We document limited uptake of the high dose influenza vac-
cine among seniors and substantial use of this vaccine off-label in
people younger than 65 y. Further research on the effectiveness
and safety of the high-dose vaccine in both on-label and off-label
populations is necessary. In particular, studies assessing the safety
of this vaccine in seniors receiving multiple does and among peo-
ple younger than 65 are warranted.
Figure 2. Cumulative number of off-label doses of high dose influenza
vaccine administered by month, 2010–2012.
Table 2. Characteristics of patients meeting enrollment eligibility and








Male sex 15,493 44.9
Physician type
Family practice doctor 9,697 28.1
Internal medicine doctor 8,229 23.9
Other 5,832 16.9
Specialist 5,212 15.1











Immunesuppression (HIV, cancer, autoimmune, transplant) 3,713 10.8
Heart disease* 3,576 10.4
Chronic liver disease 472 1.4






**27.3% of adults<50 had any immune related
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Materials and Methods
We analyzed data from the MarketScan Medicare Supplemen-
tal and Commercial Claims and Encounters databases (Copy-
right  Thomson Truven Healthcare, Inc.). Both databases
capture patient-level data on inpatient, outpatient, and prescrip-
tion drug claims, including vaccinations. The Medicare Supple-
mental database includes retirees with Medicare insurance paid
for by employers, and captures claims for the Medicare-covered
and the employer-paid portions of payment, as well as out-of-
pocket expenses. Approximately one-third of all Medicare benefi-
ciaries have employer-sponsored supplemental insurance.23,24
The Commercial Claims and Encounters database includes
claims from approximately 150 large employers and health plans
that insure employees, early retirees and dependents. These data-
bases have been used in previous vaccine studies among infants,25
adolescents,26 and to characterize trends in drug usage among
adults.27,28
To understand patterns of use of the high-dose vaccine in the
elderly, we constructed a cohort of people 65 y, who received
an influenza vaccine between January 1, 2010 and December 31,
2012. We stratify by calendar year, and focus on vaccinations
administered in August-December of each influenza season (i.e.,
vaccinations given in August through December of 2010 were
included for the year 2010). We chose to structure the analysis
into calendar years rather than influenza seasons, because the vast
majority of vaccinations (»98% in the 2010 and 2011 influenza
seasons) were administered in the fall of each influenza season.
This allowed us to maximize the data that were available and
include vaccinations that were administered in the fall of 2012,
without requiring data from the spring of 2013. Vaccinations
were identified using the following Current Procedural Termi-
nology (CPT) codes: high-dose vaccine code D 90662, and stan-
dard trivalent vaccine codes D 90655, 90656, 90657, 90658,
and 90660. Medical records were not reviewed to identify addi-
tional vaccine use. General patterns of vaccine use were described
in this population that was not subject to further enrollment cri-
teria. We evaluated doses administered by influenza season and
report frequencies of patients who received high-dose vaccine in
multiple seasons.
To further investigate associations between high-dose and sea-
sonal vaccine use in the elderly population, we subsequently lim-
ited the above cohorts to patients with continuous enrollment
from May 1 through August 31 of each year, where we assessed
patient and provider characteristics. We conducted a sensitivity
analysis to require a longer time to assess predictors and started
eligibility on March 1 (6 month window) and January 1 (8
month window). We used multivariable logistic regression to
assess the association between patient and provider variables and
high-dose influenza vaccine receipt versus standard influenza
Table 3. Predictors of off-label high-dose influenza vaccine use among adults aged 18–64 y, 2010–2012
% High-dose influenza vaccine % Standard influenza vaccine Multivariable adjusted OR (95% CI)
Total (N) 31,989 8,608,982
Age
18–35 16.8 19.0 0.83 (0.80, 0.87)
36–50 27.7 30.7 0.83 (0.81, 0.86)
51–64 55.5 50.3 Reference
Male sex 44.5 41.2 1.08 (1.05, 1.10)
Physician type
Family practice doctor 27.6 36.1 0.62 (0.61, 0.64)
Internal medicine doctor 25.3 20.0 Reference
Other 14.8 14.1 0.92 (0.89, 0.96)
Specialist 15.7 13.7 1.01 (0.98, 1.05)
Hospital doctor 1.3 1. 0.55 (0.50, 0.60)
Nurse 0.6 3.2 0.17 (0.14, 0.19)
Pharmacist 0.5 4.8 0.08 (0.07, 0.10)
Region
Northeast 17.6 22.0 Reference
North central 34.2 24.9 1.45 (1.40, 1.50)
South 34.6 34.5 1.40 (1.35, 1.44)
West 12.0 16.6 0.98 (0.94, 1.03)




13.4 10.5 1.23 (1.18, 1.27)
Heart disease* 13.1 9.1 1.30 (1.25, 1.35)
Chronic liver disease 1.8 1.4 1.08 (0.99, 1.18)
Chronic lung disease 11.4 8.9 1.25 (1.20, 1.29)
Other comorbidities
Diabetes 19.0 14.1 1.28 (1.24, 1.32)
Hypertension 34.2 28.2 1.17 (1.14, 1.21)
*IHD or MI
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vaccine. All predictors were identified a priori and included age,
sex, comorbidities, hospitalization, pneumococcal vaccination
(CPT codes 90670, 90732), type of provider who administered
the vaccine (general practitioner, specialist, pharmacist, other),
health plan type, region of residence, and rurality of residence.
Comorbidities were assessed using inpatient and outpatient diag-
noses using International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) codes. Rurality was measured
by linking the US Department of Agriculture (USDA), Eco-
nomic Research Service 2003 rural-urban continuum codes to
the claims database via 5-digit Federal Information Processing
Standard (FIPS) codes. These codes classify counties into metro-
politan or non-metropolitan categories, based on population size
and degree of urbanization. This variable was only available in
2010; therefore we did not include it in multivariable models.
Data on race and socioeconomic status were unavailable.
To understand patterns of off-label use of the vaccine, we con-
structed a cohort of people younger than 65 y, who received an
influenza vaccine during the same time period. Vaccinations
were identified using the same CPT codes as above and the same
enrollment criteria were applied to assess associations with
comorbid conditions. We categorized certain comorbidities
including: immune-compromising conditions (HIV, cancer,
transplant recipients) and general comorbidities (diabetes, hyper-
tension) and report the most frequent conditions. We used mul-
tivariable logistic regression to assess the association between
specific comorbidities and high-dose influenza vaccine receipt vs.
standard influenza vaccine among adults aged 18–64 in this
younger population.
Appendix 1 shows the ICD-9-CM codes used to define
comorbidities for both on and off-label analyses. Analyses were
conducted with SAS, version 9.3 (SAS Institute, Cary, NC). This
study was approved by the institutional review board at the Uni-
versity of North Carolina.
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18. Levêque D. Off-label use of anticancer drugs. Lancet
Oncol 2008; 9(11):1102-7; http://dx.doi.org/10.1016/
S1470-2045(08)70280-8
542 Volume 11 Issue 3Human Vaccines & Immunotherapeutics
19. Maher A, Maglione M, Bagley S, Suttorp M, Hu JH,
Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle
PG. Efficacy and comparative effectiveness of atypical
antipsychotic medications for off-label uses in adults: a
systematic review and meta-analysis. JAMA 2011; 306
(12):1359-69; PMID:21954480; http://dx.doi.org/
10.1001/jama.2011.1360
20. Furst DE, Fleischman R, Kalden J, Kavanaugh A,
Sieper J, Mease P, Smolen J, Breedveld F. Documenta-
tion of off-label use of biologics in Rheumatoid Arthri-
tis. Ann Rheum Dis 2013; 72(suppl 2):ii35-ii51;
PMID:23532442
21. Tseng HF, Sy LS, Qian L, Marcy SM, Jackson LA,
Glanz J, Nordin J, Baxter R, Naleway A, Donahue J,
et al. Safety of a tetanus-diphtheria-acellular pertussis
vaccine when used off-label in an elderly population.
Clin Infect Dis 2013; 56(3):315-21; PMID:23196953;
http://dx.doi.org/10.1093/cid/cis871
22. Lu P-j, O’Halloran A, Ding H, Williams WW, Bridges
CB, Kennedy ED. National and state-specific estimates
of place of influenza vaccination among adult popula-
tions – United States, 2011–12 influenza season. Vac-
cine 2014; 32(26):3198-204; PMID:24731815; http://
dx.doi.org/10.1016/j.vaccine.2014.04.003
23. Kaiser Family Foundation. Medicare at a glance. Menlo
Park, CA: Kaiser Family Foundation; 2012. Available
at: http://kff.org/medicare/fact-sheet/medicare-at-a-
glance-fact-sheet/. Accessed July 26, 2013.
24. Umans B, Nonnemaker KL. The medicare beneficiary
popoluation. Washington, DC: AARP Public Policy
Institue; 2009. Available at: http://assets.aarp.org/rgcen
ter/health/fs149_medicare.pdf. Accessed August 1, 2014.
25. Panozzo CA, Becker-Dreps S, Pate V, Jonsson Funk M,
St€urmer T, Weber DJ, Brookhart MA. Patterns of rota-
virus vaccine uptake and use in privately-insured US
infants, 2006–2010. PLoS One 2013; 8(9):e73825;
PMID:24066076; http://dx.doi.org/10.1371/journal.
pone.0073825
26. Tsai Y, Zhou F, Wortley P, Shefer A, Stokley S. Trends
and characteristics of preventive care visits among com-
mercially insured adolescents, 2003-2010. J Pediat
2014; 164(3):625-30; PMID:24286572; http://dx.doi.
org/10.1016/j.jpeds.2013.10.042
27. Mintzer S, Maio V, Foley K. Use of antiepileptic drugs
and lipid-lowering agents in the United States. Epilepsy
Behav 2014; 34(0):105-8; PMID:24735835; http://dx.
doi.org/10.1016/j.yebeh.2014.03.008
28. Mark TL, Joish VN, Hay JW, Sheehan DV, Johnston
SS, Cao Z. Antidepressant use in geriatric populations:
the burden of side effects and interactions and their
impact on adherence and costs. Am J Geriatr Psychiat
2011; 19(3):211-21; PMID:21425504; http://dx.doi.
org/10.1097/JGP.0b013e3181f1803d
Appendix 1. Diagnosis codes used to identify comorbidities.
Comorbidity ICD-9-CM diagnosis codes ICD-9-CM Procedure codes/HCPCS codes
Pneumonia 486
Transplant 238.77, 279.5, 996.8, V42, V5844, E8784 001.8, 009.1, 009.2, 009.3, 375.1, 419.4, 469.7, 335, 336,
410, 505, 528, 556
HIV 042, 795.71, V08
Autoimmune disease 279.4, 564.1, 696.0, 696.1, 695.4, 701.0, 710, 714, 720, 725
Cancer 140–172, 174, 175, 179–201, 173.3, 173.9, 202.0, 202.1,
202.3, 203.01, 203.8, 238.6, 273.3, 202.5, 202.6, 202.7,
202.8, 202.9, 232.9, 233.0, 233.1, 338.3, 789.51, 795.82,
799.4, V672
992.5
Infection 001–139, 320–326, 460–466, 480–490, 680–686, 254.1,
373.0, 373.1, 373.2, 382.0, 382.1, 382.2, 382.3, 382.4,
383.0, 422.0, 474.0, 491.1, 513.0, 518.6, 522.5, 522.7,
527.3, 528.3, 569.5, 573.1, 573.2, 573.3, 575.0, 575.1,
599.0, 607.1, 607.2, 608.0, 608.4, 611.0, 616.1, 616.3,
616.4, 616.8, 706.0, 730.0, 730.1, 730.2, 730.3, 730.8,
730.9, 790.7, 790.8, 998.5, 999.3, 372.0, 372.1, 372.2,
372.3, 421.0, 421.1, 572.0, 572.1, 595.0, 595.1, 595.2,
595.3, 595.4, 996.6, 254.1, 373.0, 373.1, 373.2, 382.0,
382.1, 382.2, 382.3, 382.4, 383.0, 422.0, 474.0, 491.1,
513.0, 518.6, 522.5, 522.7, 527.3, 528.3, 569.5, 573.1,
573.2, 573.3, 575.0, 575.1, 599.0, 607.1, 607.2, 608.0,
608.4, 611.0, 616.1, 616.3, 616.4, 616.8, 706.0, 730.0,
730.1, 730.2, 730.3, 730.8, 730.9, 790.7, 790.8, 998.5,
999.3, 372.0, 372.1, 372.2, 372.3, 421.0, 421.1, 572.0,
572.1, 595.0, 595.1, 595.2, 595.3, 595.4, 996.6’, 331.81,
386.33, 386.35, 388.60 422.91, 422.92, 422.93 478.21,
478.22, 478.24 478.29, 519.01, 997.62
J3370, J0690, J0713, J0692, J0696, J1580, J3260, J0278,
J1840, J1956
Sepsis 038, 995.90, 995.91, 995.92
Diabetes mellitus 250





Liver disease 070.32, 070.33, 070.54, 456.0, 456.1, 456.20, 456.21, 571,
572.3, 572.8, V427
Hypertension 401, 402.0, 402.90, 402.10, 403, 404.0, 404.10, 404.12,
404.90, 404.92, 405,
Ischemic heart disease 093.2, 402.11, 402.91, 404.11, 404.12, 404.91, 404.93, 411–
414, 420–429, 441–445, 447.1, 557.1, 557.9, 746.3,
746.4, 746.5, 746.6, 785.0, V422, V433, V434,V450, V533,
006.6, 360.6, 360.7, 929.82, 929.85, 929.80, 335.10–
335.14, 335.16–335.19
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Appendix 2. Predictors of high dose influenza vaccine among seniors 65 and older with extended baseline
windows, 2010–2012
6-month window 8-month window








Total vaccinated 18.8 - 18.9 -
Comorbidities
Hypertension 67.0 1.08 (1.07, 1.09) 70.9 1.07 (1.06, 1.09)
Infection 46.7 1.10 (1.08, 1.11) 53.7 1.10 (1.08, 1.11)
IHD 41.6 1.07 (1.06, 1.08) 45.3 1.06 (1.05, 1.08)
Diabetes 29.4 1.00 (0.99, 1.01) 30.5 1.00 (0.99, 1.01)
COPD 16.9 1.01 (0.99, 1.02) 19.1 0.99 (0.98, 1.01)
Cancer 16.2 1.04 (1.02, 1.05) 18.2 1.02 (1.01, 1.04)
Autoimmune 7.0 1.06 (1.04, 1.09) 7.9 1.05 (1.03, 1.08)
Stroke 6.9 1.08 (1.06, 1.10) 8.4 1.07 (1.05, 1.09)
Pneumonia 3.8 1.03 (1.00, 1.06) 5.0 1.04 (1.01, 1.07)
Transplant 2.0 1.08 (1.04, 1.12) 2.5 1.08 (1.04, 1.12)
Liver disease 1.3 0.93 (0.89, 0.98) 1.6 0.94 (0.91, 0.98)
MI 1.2 0.97 (0.93, 1.02) 1.5 0.96 (0.92, 1.00)
Sepsis 1.0 0.90 (0.85, 0.95) 1.2 0.90 (0.85, 0.94)
HIV 0.04 0.49 (0.38, 0.62) 0.04 0.50 (0.39, 0.64)
Hospitalization 12.9 1.04 (1.02, 1.06) 16.6 1.05 (1.03, 1.07)
Pneumococcal vaccine 9.3 1.09 (1.07, 1.11) 10.3 1.10 (1.08, 1.12)
IHDD Ischemic heart disease; COPD D Chronic obstructive pulmonary disease; MI DMyocardial infarction; HIV D Human immunodeficiency virus.
*Adjusted for month of vaccine receipt and all other predictor variables in Table 1 except for rurality.
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